Home › Funds › Defender Capital, LLC. › LCTX

Defender Capital, LLC. position in LCTX

LINEAGE CELL THERAPEUTICS IN · Health Care

Defender Capital, LLC. reported holding 6,648,899 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$6.4M, representing 1.99% of its reported portfolio and ranking #14 among its reported holdings. Defender Capital, LLC. has disclosed LCTX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)6.65M sh
Reported value held$6.35M
Portfolio Weight1.99%
First reportedQ3 2023
Last changeAdd
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Defender Capital, LLC.'s LCTX position evolved

Defender Capital, LLC. first disclosed a stake in LCTX in Q3 2023 at 5,184,510 shares (US$6.1M). The position peaked in Q4 2025 at 6,829,099 shares, worth US$11.4M. Across 12 filings, Defender Capital, LLC. increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 6,648,899 shares valued at US$6.4M — an increase of 50,000 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.18M $6.12M New
Q4 2023 4.97M $5.42M Reduce
Q1 2024 4.97M $7.35M Hold
Q2 2024 4.97M $4.96M Hold
Q3 2024 5.00M $4.53M Add
Q4 2024 5.96M $3.00M Add
Q1 2025 6.31M $3.16M Add
Q2 2025 6.79M $6.16M Add
Q4 2025 6.83M $11.41M New
Q1 2026 6.73M $10.63M Reduce
Q2 2026 6.60M $8.64M Reduce
Q3 2026 6.65M $6.35M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LCTX and 13F data

LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 36 other funds we track also report a position in LCTX — the largest reported positions include BROADWOOD CAPITAL INC (US$64.9M), RAFFLES ASSOCIATES LP (US$6.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LCTX

All LCTX fund holders →

FAQ

How long has Defender Capital, LLC. held LCTX?

Defender Capital, LLC. has disclosed LCTX holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is Defender Capital, LLC.'s current position in LCTX?

As of Q3 2026, Defender Capital, LLC. holds 6.65M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $6.35M, representing 1.99% of its reported portfolio and ranking #14.

Has Defender Capital, LLC. been buying or selling LCTX?

In the latest 13F filing (Q3 2026), Defender Capital, LLC. increased its position in LCTX. The position peaked in Q4 2025 at 6.83M shares.

Which other funds hold LCTX?

Other major institutional holders of LCTX include BROADWOOD CAPITAL INC, RAFFLES ASSOCIATES LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.